This study is currently recruiting.

Description: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy (Neurocrine).

Eligibility & Criteria

IRB #: IRB00391760

Principal Investigator: Heather Riordan, MD

Eligible Age Range: All

Gender: All

Diagnosis: Children and adults with Dyskinetic Cerebral Palsy

Click here to view study flyer.